These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7285526)

  • 1. [Clinical use of calcitonin in the treatment of osseous localizations in breast carcinoma and multiple myeloma].
    Di Benedetto G; Corsini G; Puppo F; Zavarise GM
    Clin Ter; 1981 Mar; 96(6):605-13. PubMed ID: 7285526
    [No Abstract]   [Full Text] [Related]  

  • 2. Human calcitonin and malignant osteolysis.
    Nuti R; Righi G; Turchetti V; Vattimo A; Lazzaretto R; Martini G
    Panminerva Med; 1986; 28(1):5-9. PubMed ID: 3960585
    [No Abstract]   [Full Text] [Related]  

  • 3. [Synthetic salmon calcitonin in the therapeutic management of osteolytic metastases of breast carcinoma].
    Simone C; Racanelli A
    Clin Ter; 1981 Aug; 98(3):247-67. PubMed ID: 7285537
    [No Abstract]   [Full Text] [Related]  

  • 4. [Salmon calcitonin in supportive therapy of neoplastic osteolysis. Preliminary report on a case of myeloma].
    Andriani A; Beni A; Beni RA; Calistri A; Gelli GF
    Clin Ter; 1981 Jan; 96(2):183-91. PubMed ID: 7237953
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
    Delmas PD; Charhon SA; Chapuy MC; Meunier PJ
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):663-6. PubMed ID: 6523018
    [No Abstract]   [Full Text] [Related]  

  • 7. Agents affecting osteolysis in patients with breast cancer.
    Coombes RC; Neville AM; Gazet JC; Ford HT; Nash AG; Baker JW; Powles JT
    Cancer Chemother Pharmacol; 1979; 3(1):41-4. PubMed ID: 161206
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple myeloma: optimal use of salmon calcitonin in the management of myeloma osteoclastic bone disease.
    Bataille R; Tenoudji-Cohen M; Rossi JF
    Br J Haematol; 1983 Jan; 53(1):170-1. PubMed ID: 6848121
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biphosphonates. Contribution to the treatment of malignant osteolysis].
    Prier A
    Presse Med; 1992 Jul 4-11; 21(25):1143-5. PubMed ID: 1409460
    [No Abstract]   [Full Text] [Related]  

  • 10. Conventional radiograms for assessment of salm-calcitonin therapy for bone metastases from breast carcinoma.
    Geyer J; Quadt C; Perlick E; Starke K; Stier G; Tanneberger S
    Eur J Radiol; 1991; 12(2):124-6. PubMed ID: 2036999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reconstruction of metastatically destroyed skeletal parts following radiologic-cytostatic-hormonal and orthopaedic therapy (author's transl)].
    Barndt J
    Radiobiol Radiother (Berl); 1977; 18(5):619-24. PubMed ID: 609725
    [No Abstract]   [Full Text] [Related]  

  • 12. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
    Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous pamidronic acid: new indications. Useful palliative treatment for osteolysis.
    Prescrire Int; 1998 Aug; 7(36):103-5. PubMed ID: 10342945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of calcitonin in neoplastic osteolysis].
    Pastorino G; Bianucci M
    Minerva Med; 1983 Mar; 74(13):707-14. PubMed ID: 6835560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphosphonates for osteolytic metastases.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
    Lancet; 1985 May; 1(8438):1155-6. PubMed ID: 2860356
    [No Abstract]   [Full Text] [Related]  

  • 18. The potential role of bisphosphonates in prostate cancer.
    Oades GM; Coxon J; Colston KW
    Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone metastases from breast cancer treated with calcitonin. Case report.
    Favini G; Arosio A; Libretti A
    Tumori; 1979 Dec; 65(6):713-7. PubMed ID: 543014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of bone metastases].
    Tubiana-Hulin M
    Bull Cancer Radiother; 1996; 83(4):299-304. PubMed ID: 9081331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.